🇺🇸 FDA
Pipeline program

Tabelecleucel

ATA129-NPC-202

Phase 2 mab terminated

Quick answer

Tabelecleucel for Nasopharyngeal Carcinoma is a Phase 2 program (mab) at Atara Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Atara Biotherapeutics
Indication
Nasopharyngeal Carcinoma
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials